ReviewFrontiers in immunology2026
Mechanisms of T cell-mediated antitumor immunity within tertiary lymphoid structures.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tertiary lymphoid structures (TLS) are ectopic lymphoid-like organs formed under chronic inflammatory stimulation, which have been increasingly recognized as indicators of favorable clinical prognosis and enhanced immunotherapy response in multiple solid tumors. T cells are essential constituents of TLS, involved in their formation, maintenance, and immune function. They exhibit substantial heterogeneity in quantity, phenotype, and spatial localization across different tumor types. Follicular helper T (Tfh) cells act as a central subset in TLS by promoting B cell activation, germinal center (GC) development, and antibody production. They have been widely regarded as key predictors of favorable therapeutic response and prolonged survival. In addition, peripheral helper T (Tph) cells, regulatory T (Treg) cells, and follicular regulatory T (Tfr) cells also perform immunomodulatory functions within TLS. Their effects can either enhance or suppress antitumor responses, depending on the tumor type, TLS spatial distribution, and maturation status. This review examines the phenotypic heterogeneity, functional fate, and intercellular interactions of T cells within TLS. It also explores the immunoregulatory role of TLS and their potential in novel immunotherapy strategies. Further research should aim to the evolution process of immune populations within TLS and standardized model establishment, in order to accelerate their clinical translation in precision immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.